Publicaciones (89) Publicaciones de Berta Esperanza Lasheras Aldaz

2017

  1. Barriers to promote cardiovascular health in community pharmacies: A systematic review

    Health Promotion International, Vol. 32, Núm. 3, pp. 535-548

2013

  1. Factors associated To medication changes in institutionalized elderly people

    Atencion Farmaceutica, Vol. 15, Núm. 3, pp. 158-170

2009

  1. Effects of neonatal stress on markers of synaptic plasticity in the hippocampus: Implications for spatial memory

    Hippocampus, Vol. 19, Núm. 12, pp. 1222-1231

  2. Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: Involvement of the HPA axis

    Psychoneuroendocrinology, Vol. 34, Núm. 10, pp. 1495-1505

  3. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine 3,4-methylenedioxymethamphetamine-induced 5-HT toxicity in the rat: XXX Congreso Nacional de la SEF

    Actualidad en farmacología y terapéutica, Vol. 7, Núm. 1, pp. 71-73

  4. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine- induced 5-HT deficits in the rat

    Journal of Neurochemistry, Vol. 108, Núm. 3, pp. 755-766

2008

  1. Barreras para la notificación de sospechas de RAM en farmacias de Navarra

    E-farmacéutico comunitario: revista de la Sociedad Española de Farmacia Comunitaria, Vol. 3, Núm. 3, pp. 12-16

  2. Competencias para el desarrollo de la atención farmacéutica

    Pharmaceutical care España, Vol. 10, Núm. 3, pp. 106-119

  3. Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats

    Neuroscience, Vol. 154, Núm. 4, pp. 1218-1226

  4. Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: Effect of antidepressant treatment

    Psychopharmacology, Vol. 199, Núm. 1, pp. 1-14

  5. Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin depletions: Role of mitochondrial ATP-sensitive potassium channels, Akt and ERK

    Journal of Neurochemistry, Vol. 104, Núm. 4, pp. 914-925

  6. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats

    Neuropharmacology, Vol. 54, Núm. 5, pp. 885-900

  7. Placebos y efecto placebo

    Medicamentos, placebos y fraudes (Formación Alcalá), pp. 49-60

  8. The relationship between core body temperature and 3,4- methylenedioxymethamphetamine metabolism in rats: Implications for neurotoxicity

    Psychopharmacology, Vol. 197, Núm. 2, pp. 263-278

2007

  1. Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats

    Psychoneuroendocrinology, Vol. 32, Núm. 3, pp. 256-266

  2. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1)

    European Journal of Neuroscience, Vol. 25, Núm. 1, pp. 281-290

  3. Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats

    European Journal of Pharmacology, Vol. 562, Núm. 3, pp. 198-207

2006

  1. Effect of selective cholinergic denervation on the serotonergic system: Implications for learning and memory

    Journal of Neuropathology and Experimental Neurology, Vol. 65, Núm. 11, pp. 1074-1081

  2. Studies on striatal neurotoxicity caused by the 3,4- methylenedioxymethamphetamine/malonate combination: Implications for serotonin/dopamine interactions

    Journal of Psychopharmacology, Vol. 20, Núm. 2, pp. 245-256

2005

  1. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease

    Neuropsychologia, Vol. 43, Núm. 3, pp. 442-449